Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with BRAF V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-09, Vol.383 (12), p.1139-1148
Hauptverfasser: Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M, Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V, Schadendorf, Dirk
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvants
Inhibitor drugs
Melanoma
Metastases
Metastasis
Mutation
Survival
Survival analysis
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with BRAF V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2005493